Monthly Archives: May 2020

GermWrap Disinfection Opens in Dallas to Aid Post Pandemic Reopening

GermWrap’s professional electrostatic services will enable companies, in the Lone Star State, to resume their business endeavors in a post-lockdown era.

May 28, 2020 / / —

May 19th, 2020. TX, USA: Houston-based electrostatic disinfection company, GermWrap, has announced the opening of a new office based in the heart of Dallas. The new service area will allow businesses to reopen safely by disinfecting their brick-and-mortar locations in an efficient and affordable manner.

Comprehensive Disinfection To Support Businesses In This Difficult Time

As the lockdown restrictions across the country start to relax, organizations in the Lone Star State are now planning to reopen their doors to the public. At a time where the prevention of viral and bacterial infections is greater than ever! GermWrap’s comprehensive electrostatic disinfection treatments can speed up the process of reopening, while the company’s new office allows the Houston-based company to extend its services to businesses throughout Dallas and North Texas.

GermWrap disinfection services can be used in any physical setting, ranging from offices to shop floors, warehouses to manufacturing plants, as well as churches, gyms, restaurants, and schools. By killing 99.9999% of pathogens through a touchless application, the electrostatic disinfection process allows companies to protect employees and customers alike by eliminating any presence of COVID-19.

Using Coulomb’s Law, the disinfection techniques are EPA approved for COVID-19 eradication on all surfaces, while also meeting AOAC testing requirements for hospital disinfection and OSHA’s Bloodborne Pathogen Guidelines. The electrostatic disinfection process is also a child and pet-friendly solution, that can treat an entire room within a matter of seconds.

GermWrap’s new Dallas office offers emergency applications for businesses wanting to open their doors immediately, while routine treatments will ensure that workspaces remain safe throughout the months where COVID-19 is set to linger. Aside from killing the coronavirus, the broad-spectrum disinfectant prevents the spreading of other viruses and illnesses.

A full 360-degrees of coverage, that even hits the hard to reach places, enables companies to get back to business safely and efficiently without causing major disruption to ongoing operations. It is the ideal solution for firms of varying industries, sizes, and backgrounds.

About GermWrap

GermWrap is one of the Lone Star State’s premier commercial disinfectant companies. They provide a level of hygienic cleanliness that surpasses the work of standard disinfection companies. The experts have supported a wide range of clients including Texaco, Plastipak, DentaLand, The Regis School, ULINE, Beard Papa’s, State Farm, Doucet Med Spa, and the NEA Group.

Boasting a reputation for producing fast and efficient disinfectant services, the business has already helped dozens of companies stay open during the pandemic and prepare for the post-lockdown reopening from its Houston and Central Texas offices. Thanks to the opening of the new site, even more businesses can now benefit from their innovative services.

GermWrap’s commitment to professionalism, fast times, and transparent communication are integral features at any time. However, those attributes are set to be even more crucial during these unprecedented times. The services are available with immediate results.

More information is available at germwrap.com. Alternatively, GermWrap’s press contact Jeanette Gonzalez can be contacted at 832-612-7740 or jeanette@germwrap.com.

Contact Info:
Name: Jeanette Gonzalez
Email: Send Email
Organization: GermWrap
Phone: 832-612-7740
Website: https://germwrap.com/

Source:

Release ID: 88959513

Winmark Offering Custom COVID-19 Safety Signs To Reopening Businesses

Online stamp & sign business, Winmark, is now offering a wide range of custom COVID-19 safety signs. These signs can be used by businesses to communicate health & safety policies and to update customers on closures, essential business status, and more.

May 28, 2020 / / —

Across the country, businesses are looking at the prospects of opening their doors as lockdown restrictions ease. However, the COVID-19 outbreak has resulted in uncertain times for many businesses, who wish to keep their customers and their staff as safe from the risk of infection as possible. In order to help businesses establish and communicate the policies that keep everyone safe, Winmark Stamp & Sign Incorporated is offering custom COVID-19 Safety Signs.

The range of COVID-19 Safety Signs from Winmark includes signs that communicate guidelines on social distancing, restrictions to existing business operations, provisions for older and more at-risk customers, and much more. The signs can all be customized to suit the needs and circumstances of the client, including business names and contact details. The team at Winmark can custom create signs for clients, using any text or imagery of their choice, with a series of templates to work from.

As such, businesses can carefully consider which temporary pandemic procedures they need to put in place and ensure that they have the appropriate signage to communicate that to their customers. Clients can also keep customers informed about their business statuses, such as whether they are open as essential business, only open as a curbside pickup business, open at certain times for specific customers, and more.

Whether a client’s business has had to close their doors during the COVID-19 outbreak and are looking to update their customers about how and when they are opening, or they have remained open as an essential business, Winmark Stamp & Sign Incorporated works with clients directly to make sure that messaging on their signs is accurate and specific.

There are a wide range of sign templates available, such as their Essential Business, Temporary Closure, Social Distancing, Wash Your Hands, and Hospital & Medical Professional Signs. All of these signs can be custom-designed to meet the client’s individual needs.

Winmark Stamp And Sign is taking every precaution to help reduce the spread of COVID-19 and aim to help businesses that wish to do the same. As such, you can learn more about their COVID-19 signage for business and about the company at https://winmarkstampandsign.com/covid-19-coronavirus-signage-for-businesses/.

END

Notes for the Editor: Please send any and all press inquires directly to Brian Szwedko at the Winmark HQ, which can be found at 2284 S W Temple Salt Lake City, UT 84115 or called on 801-486-2011. All email inquiries can be sent to sales@winmarkinc.com.

Contact Info:
Name: Brian Szwedko
Email: Send Email
Organization: Winmark
Address: 2284 S W Temple Salt Lake City, UT 84115
Phone: 801-486-2011
Website: https://winmarkstampandsign.com/

Source:

Release ID: 88959515

Assisted Living COVID Safety Protocols | griffinliving.com

During the COVID-19 crisis, safety is more important than ever in senior living centers. Here’s how Griffin Living is keeping their staff and residents safe at their Assisted Living Facilities.

Calabasas , United States – May 28, 2020 /MarketersMedia/ —

Following up on my colleague John Terando’s piece about how the team at Griffin Living are implementing safety protocols for workers in the corporate office and on the construction sites , I want to share what Griffin Living, as a top assisted living community builder, is doing to keep residents and staff safe at our assisted living facilities.

Griffin Living is implementing the following precautions, based on the guidelines from the CDC (Centers for Disease Control and Prevention) and CMS (Centers for Medicare and Medicaid Services), as well as input from senior project managers. Some of them were underway before the COVID crisis because of a severe flu season in 2018. Highlights of our disease prevention work include:

Filtering air to the ASHRAE 170 standard used for healthcare facilities

HVAC systems in Griffin Living facilities will turn air over every 4 hours instead of the usual 24 in resident rooms and common areas. The air quality matches surgical center standards. We are installing UV lights in the HVAC and placing copper mesh in the ductwork to reduce airborne pathogens.

Disinfecting surfaces and increasing contactless access

As an innovative senior living facility, Griffin Living is placing UV lights on high traffic surfaces (e.g. tables in our kitchens) and antimicrobial coatings on handrails and chairs that are frequently touched. Touchless hand-sanitizing stations are located throughout the building. Additionally, we are outfitting entries with RFID proximity sensors to unlock doors so that residents can access rooms hands-free. Finally, when new residents are moving in, the units will be disinfected and sealed until the occupant opens the door for the first time.

Maintaining social distance

To facilitate social distancing, Griffin Living Projects will stagger mealtimes to limit the number of residents in the dining rooms. Specific areas are designated for visitors so that these spaces can be disinfected after every visit. Visitors will be briefed on best hygiene practices and instructed to contact Griffin Living if they experience symptoms within two weeks of their visit.

Implementing new staffing protocols

Each project will have an infection prevention and control specialist to assume an expanded role from what the activities directors usually do in assisted living facilities to ensure cleanliness. The team of senior living community developers at Griffin Living are also changing our staffing model so that only 4-5 people have contact with each patient per week. To accomplish this, staff members will be cross-trained and certified to perform a number of services. This will be an investment, but it will result in better customer service and higher staff retention in the long-term.

Increasing medical precaution

Griffin Living will use infrared contactless thermometers to take the temperature of residents, visitors, and staff before they enter the buildings. For staff and residents with known exposure, temperatures will be taken up to four times per day.

Providing telemedicine access

Griffin Living facilities are installing video access in exam rooms so that physicians can be consulted with minimal trips to the doctor’s office, even for regular appointments. Staff will be present to take vitals.

In addition, emergency calls can be fielded from patients’ rooms 24 hours a day, saving costly trips to the ER. During this crisis, doctors and nursing staff have been forced to become comfortable with the doctor consulting remotely. At Griffin Living, nurses and patients can talk to the doctor from the comfort of the patient’s apartment. The expansion of telehealth options will prove to be one of the greatest changes in medical protocol in the last twenty years.

The team at Griffin Living are implementing these practices, and exploring many more as information about data-backed interventions is released. Though the reporting around senior living paints a bleak picture, we are confident at Griffin Living that we can provide an enriching and safe place at our assisted living facilities for seniors to embrace their next phase of life.

Anne Lewis is Executive Vice President and COO of Griffin Living. Griffin Living is owned and managed by Paul Griffin III, a fifth-generation real estate developer. Through the past 117 years, various Griffin entities have developed an excess of 10 billion dollars of residential, commercial, office and master-planned communities. Griffin Living is a residential and commercial real estate development company, with numerous and varied community investment partners. The company is striving to be one of the top senior living developers, providing senior living options when Americans need them most.

Contact Info:
Name: Aurora Griffin
Email: Send Email
Organization: Griffin Living
Website: https://griffinliving.com/

Source URL: https://marketersmedia.com/assisted-living-covid-safety-protocols-griffinlivingcom/88959336

Source: MarketersMedia

Release ID: 88959336

U.S. Office for Civil Rights to Join EHNAC and CORL Technologies for Webinar on Privacy & Security Enforcement Activities

Panelists to discuss current compliance activities, perspectives on HIPAA/HITECH enforcement focused on downstream vendors and business associates

FARMINGTON, CT / ACCESSWIRE / May 28, 2020 / The Electronic Healthcare Network Accreditation Commission (EHNAC), a non-profit standards development organization and accrediting body for organizations that electronically exchange healthcare data, today announced a collaboration with CORL Technologies on an upcoming webinar titled OCR 2019-2020 Year in Review and Lessons Learned . The event, featuring Serena Mosley-Day, Senior Advisor for HIPAA Compliance and Enforcement, Office for Civil Rights (OCR), will take place on Wednesday, June 10 from 1:30pm to 3pm EST.

Webinar attendees will hear from the OCR and other industry experts on key findings resulting from the aftermath of 11 organizations having settled or received enforcement actions over the course of 2019. Panelists will walk attendees through detailed examples, comparing and contrasting the issues as well as the required Resolution Agreements & Corrective Action Plans – paying specific focus on downstream vendor and business associates.

"Much can be learned from examining the OCR's activities and perspectives on HIPAA and HITECH enforcement. During this webinar, we'll be focusing the conversation on downstream vendors and business associates which will give organizations better insight on areas to strengthen internally so they can plan and remediate accordingly," said Lee Barrett, Executive Director and CEO, EHNAC who is also a webinar panelist. "We're looking forward to partnering with CORL to bring this important topic to the industry, so organizations can learn how to leverage best practices to reduce risk across privacy and security."

Joining Mosely-Day and Barrett will be Cliff Baker, CEO & Co-Founder, CORL Technologies and Lesley Berkeyheiser, Senior Reviewer & Practitioner, EHNAC. The panel of subject matter experts will discuss current compliance activities, best practices and practical steps to decrease privacy, security and cybersecurity risk, with a focus on vetting downstream business associates and vendors.

For more information or to register for the webinar, visit: https://register.gotowebinar.com/register/261783130648375055

About EHNAC

The Electronic Healthcare Network Accreditation Commission (EHNAC) is a voluntary, self-governing standards development organization (SDO) established to develop standard criteria and accredit organizations that electronically exchange healthcare data. These entities include accountable care organizations, data registries, electronic health networks, EPCS vendors, e-prescribing solution providers, financial services firms, health information exchanges, health information service providers, management service organizations, medical billers, outsourced service providers, payers, practice management system vendors, third-party administrators and trusted networks. The Commission is an authorized HITRUST External Assessor, making it the only organization able to provide both EHNAC accreditation as well as to conduct HITRUST CSF assessment services.

EHNAC was founded in 1993 and is a tax-exempt 501(c)(6) nonprofit organization. Guided by peer evaluation, the EHNAC accreditation process promotes quality service, innovation, cooperation and open competition in healthcare. To learn more, visit www.ehnac.org, contact info@ehnac.org, or follow us on Twitter, LinkedIn and YouTube.

Press contact information:

Tom Testa, Anderson Interactive
617-872-0184
tom@andersoni.com

Debra Hopkinson, EHNAC
860-408-1620
dhopkinson@ehnac.org

SOURCE: Electronic Healthcare Network Accreditation Commission (EHNAC)

ReleaseID: 591695

PJSC Mechel : Mechel Ups Sales of Railway Products

MOSCOW, RUSSIA / ACCESSWIRE / May 28, 2020 / Mechel PAO (MOEX:MTLR) (NYSE:MTL), one of the leading Russian mining and metals companies, reports increased sales of rails and sections for wagon building over the first four months of 2020.

Over these months, Chelyabinsk Metallurgical Plant has shipped 3.5 times more rails year-on-year, with sales totaling 145,000 tonnes. Rail exports have more than doubled during this period. The plant has also signed its first contract with Georgian Railways and began shipping, as well as signed yet another contract with Belarus Railways. Customers of the plant's rails also include projects of Russia's Defense Ministry and several Russian steelmakers. Chelyabinsk Metallurgical Plant also signed a contract with Uzbekistan Railways for Z-sections which are used in wagon building.

So far in 2020 Izhstal supplied the Moscow Metro with some 5.400 tonnes of conductor rails used for construction and modernization of the Russian capital's underground transit system. In 2019, Izhstal shipped nearly 6,000 tonnes of conductor rails. Apart from Moscow, other Russian cities that are either constructing or repairing their metro systems – such as Kazan and Saint-Petersburg – voiced their interest in the plant's output. In May, the plant received a certificate of compliance for its conductor rails from the voluntary wagon building product certification agency.

"Our facilities continue to increase output and sales of railway products and develop exports even as the pandemic forced economic activity into a recession. This is proof of our products' high quality and market demand," Mechel PAO's Chief Executive Officer Oleg Korzhov noted.

CONTACT:

MechelPAO
EkaterinaVideman
Tel: + 7 495 221 88 88
ekaterina.videman@mechel.com

Mechel is an international mining and steel company. Its products are marketed in Europe, Asia, North and South America, Africa. Mechel unites producers of coal, iron ore concentrate, steel, rolled products, ferroalloys, heat and electric power. All of its enterprises work in a single production chain, from raw materials to high value-added products.

Some of the information in this press release may contain projections or other forward-looking statements regarding future events or the future financial performance of Mechel, as defined in the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. We wish to caution you that these statements are only predictions and that actual events or results may differ materially. We do not intend to update these statements. We refer you to the documents Mechel files from time to time with the U.S. Securities and Exchange Commission, including our Form 20-F. These documents contain and identify important factors, including those contained in the section captioned "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in our Form 20-F, that could cause the actual results to differ materially from those contained in our projections or forward-looking statements, including, among others, the achievement of anticipated levels of profitability, growth, cost and synergy of our recent acquisitions, the impact of competitive pricing, the ability to obtain necessary regulatory approvals and licenses, the impact of developments in the Russian economic, political and legal environment, volatility in stock markets or in the price of our shares or ADRs, financial risk management and the impact of general business and global economic conditions.

SOURCE: PJSC Mechel

ReleaseID: 591785

Grapefruit/GPFT Announces Filing Amendment No. 3 to Key Funding Registration Statement; Plans to Formally Reapply to OTCQB

LOS ANGELES and DESERT HOT SPRINGS, CA / ACCESSWIRE / May 28, 2020 / Grapefruit USA, Inc., (OTC PINK:GPFT) ("Grapefruit" or the "Company") a California based cannabis company, is announcing today that it filed Amendment No. 3 to its resale Registration Statement on Form S-1. The Registration Statement covers the resale of shares to be issued to the Company's institutional investor, Auctus Fund, LLC (the "Investor") of Boston, MA upon conversions of Convertible Notes (the "Notes") previously issued to Auctus in to GPFT common stock at approximately 95% of the market price and upon exercise of callable cash exercise-only Warrants issued by the Company to Auctus when the Notes were originally issued. Upon effectiveness of the registration statement, the Investor is obligated to immediately provide an additional tranche of funds to Grapefruit and additional funds ninety (90) days later. When all of the Notes are issued and if the Warrants are fully exercised (including via the Company being able to exercise its call provision), Grapefruit will have received $10,000,000.00 of proceeds from these financing transactions. Grapefruit intends to commence the filing of the OTCQB application next week. As Grapefruit previously disclosed in its January 31, 2020 Press Release, the OTC staff has indicated that Grapefruit will be relisted on the OTCQB upon effectiveness of the Registration Statement.

With respect to Grapefruit's filing and the OTCQB reapplication, Bradley J. Yourist, Grapefruit's CEO, stated, "We are very pleased to file this Amendment. We are looking forward to relisting on the OTCQB which will increase the number of investors who may purchase our stock in the open market. We continue to be on track to finalize the Auctus financing transaction. Pursuant to the terms of our agreements with Auctus, immediately upon effectiveness of the Registration Statement, we will receive additional funds from the Investor and, 90 days following effectiveness, a final Convertible Note Tranche of $1,000,000.00. These funds are key to our revenue growth in 2020, which is already off to an increase over last year. In addition, if our common stock price increases, we will be calling our warrants to bring in additional working capital. We are also in the process of evaluating other capital raising possibilities. We have obviously regained our momentum which was temporarily slowed by the delay in the Grapefruit Boulevard Investments, Inc. audit and look forward to the second half of 2020 and beyond and what we believe are the unlimited possibilities the future holds for Grapefruit. Revenues from our distribution operations are growing at a steady pace and progress with our potentially disruptive patented time-released THC+CBD "Patchless Patch" continues unabated. We expect to bring our "Patchless Patch" to market by the end of June 2020."

To learn more about Grapefruit's THC + CBD Topical Cream please visit our website at:
https://grapefruitblvd.com/grapefruits-patented-time-release-thc-patchless-patch-topical-cream/

To learn more about Grapefruit, please visit our website at:
https://grapefruitblvd.com/investor-relations/

About GRAPEFRUIT

Grapefruit's corporate headquarters is in Westwood, Los Angeles, California. Grapefruit holds California permits and licenses to both manufacture and distribute cannabis products. Grapefruit's extraction laboratory and distribution facilities are located in the industry recognized Coachillin' Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, located on the extension of North Canyon Rd., approximately 14 miles north of downtown Palm Springs. Grapefruit obtained its California cannabis licenses in January 2018 and commenced distribution of cannabis products thereafter. Grapefruit's vision remains to become a seed to sale, fully vertically integrated ethical and compliant cannabis product Company. To obtain further information on Grapefruit and its operations, please visit its website at https://grapefruitblvd.com/. To learn more about Grapefruit's Sugar Stoned branded line of cannabis and CBD infused edibles, please visit us at https://sugarstoned.com/.

Safe Harbor Statement

Imaging3 cautions you that any statement included in this press release that is not a description of historical facts is a forward-looking statement. Many of these forward-looking statements contain the words "anticipate," "believe," "estimate," "may" "intend," "expect" and similar expressions. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the company and are subject to a number of risks and uncertainties inherent in Grapefruit's business, including, without limitation: the company may not ever obtain additional funds necessary to support its business development and growth plans; and the company may not ever achieve the market success to reach or sustain a profitable business. In addition, there are risks and uncertainties related to economic recession or terrorist actions, competition from much larger cannabis companies, unexpected costs and delays, potential product liability claims, and many other factors. More detailed information about Grapefruit and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q/A for the period ended March 31, 2020 and its Registration Statement on Form S-1/A. Such documents may be read free of charge on the SEC's website at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Grapefruit undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Investor Relations Contact:

Bradley Yourist
brad@grapefruitblvd.com
18776 Blue Dream Crossing, Unit LL1 53-07
Desert Hot Springs, California 92240
(760) 205-1382
https://grapefruitblvd.com/

SOURCE: Grapefruit USA

ReleaseID: 591741

Eco-Growth Strategies Moves Forward with acquisition of Hara

Company is Expecting to Close in Q2 2020

SACRAMENTO, CA / ACCESSWIRE / May 28, 2020 / Eco-Growth Strategies (the "Company" or "Eco-Growth Strategies") (OTC PINK:ECGS), a nutraceutical company developing a variety of premium CBD-based products specializing in sourcing and extraction of trusted North American hemp, today announced that the company is moving forward with the proposed purchase of HARA, www.haraflow.com. As disclosed previously, HARA is an ultra-premium hemp-based CBD company that focuses on athletes, fitness-minded individuals as well as those interested in improving their personal well being. The company also intends to produce products for both the beauty and pet segment as well. The handcrafted catalog of products contains no THC and is produced with the highest quality CBD. The company has projected 150% year over year growth, 70% repeat customer rate and has generated $354,000 of revenue in approximately the last 14 months.

"We are thrilled to be moving along with the purchase of HARA. Their suite of quality CBD products will fit in nicely into the corporate structure at Eco-Growth. We intend on growing Eco-Growth through similar bolt on acquisitions" commented William Delgado, Chairman and CEO of Eco-Growth Strategies.

The closing is subject to a final merger agreement along with proxy materials executed by the shareholders of HARA. The closing is expected by the end of the second quarter 2020.

About Eco-Growth Strategies, Inc. A/K/A Falcon Technologies, Inc.

Eco-Growth Strategies, Inc. is a nutraceutical and processing company developing a range of CBD-based products. The company's mission is to employ best practice science to source, manufacture, and package the process all of its CBD products from within the United States. The company performs farm and manufacturing site visits and sources its products from only the highest quality hemp farms in North America.

CBD Disclaimer

The statements made regarding CBD products including our future products have not been evaluated by the Food and Drug Administration. The efficacy of these products and the testimonials made has not been confirmed by FDA- approved research. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from healthcare practitioners. Please consult your healthcare professional about potential interactions or other possible complications before using any product. The Federal Food, Drug, and Cosmetic Act requires this notice.

SAFE HARBOR ACT

Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Richard Brown
rbrown@nesscc.com
978-767-0048
https://ecogrowthstrategies.com/our-team/

SOURCE: Eco-Growth Strategies

ReleaseID: 591756

StageZero Life Sciences Discusses Testing for COVID-19 Beginning to Go Live and Whole Blood Diagnostic Test, Aristotle(R), in New Video Interview on SNN Network

LOS ANGELES, CA / ACCESSWIRE / May 28, 2020 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Video Interview with James Howard-Tripp, Chairman and CEO of StageZero Life Sciences Ltd. (TSX:SZLS). StageZero Life Sciences is dedicated to the early detection of cancer and multiple disease states through whole blood, according to the company's website (see here: www.stagezerolifesciences.com).

Click the following link to watch the Video Interview:

StageZero Life Sciences – Molecular Diagnostics Company Discusses Testing for COVID-19 and Whole Blood Diagnostic Test, Aristotle®

You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE

Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer

About StageZero Life Sciences

StageZero Life Sciences is dedicated to the early detection of cancer and multiple disease states through whole blood. Aristotle®, our next generation test, is a panel for simultaneously screening for 10 discrete cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on our proven and proprietary Sentinel Principle Technology Platform which has been validated on 10,000 patients and used to develop the first liquid biopsy for Colorectal Cancer, with further validation currently underway. In addition to building a pipeline of products for early cancer detection, the Company operates a CAP accredited and CLIA certified reference laboratory based in Richmond, Virginia that offers the ColonSentry® test as well as licensed biomarker tests for breast and prostate cancers. To learn more visit www.stagezerolifesciences.com.

About SNN Network

SNN Network is an investor portal covering the Small-, Micro- and Nano-cap markets by providing news, insights, education tools and expert commentary. Subscribe now to our YouTube Channel to be notified when new CEO video interviews, Wall Street Views with investing experts, and Planet MicroCap Podcast episodes are available.

Subscribe NOW to SNN Network: http://bit.ly/1Q5Yfym
SNN Network
info@snnwire.com

SOURCE: Stock News Now

ReleaseID: 591759

GoldON Receives MAG Survey Results and Hires Orix Geoscience for Project Data Interpretation at Slate Falls Gold-Silver Property

New high-resolution airborne MAG survey reveals prominent structural features throughout the Property

VICTORIA, BC / ACCESSWIRE / May 28, 2020 / GoldON Resources Ltd. (TSXV:GLD) ("GoldON" or the "Company") is pleased to provide an update on the exploration status of its 100% owned Slate Falls gold-silver property (the "Property") located in the Patricia Mining Division of northwestern Ontario. The 5,656-hectare Property lies within the southwestern extension of the Meen-Dempster Greenstone Belt between the Red Lake and Pickle Lake gold camps (see Figure 1).

GoldON hired Prospectair Geosurveys to complete a heliborne high-resolution magnetic (MAG) survey to cover the Property that included 50-metre flight line spacings for a total of 1,247-line kilometres (km). The final report detailing the results of the MAG survey has been received and the data reveals prominent structural features exist throughout the Property. The image below (Figure 4) illustrates the significant difference in structural detail between the historical MAG data on the left (Figure 2) and the new MAG data on the right (Figure 3). This new high-resolution information will aid in reinterpreting the various lithologies and give a far better understanding of the intricate structure, folding, shearing and faulting that has been mapped on the Property.

Figure 4 – Includes overlays of historical data and preliminary interpreted fold axis and limbs

While GoldON's primary focus to date has been on the numerous historical high-grade gold and silver showings that are part of the Slate Falls Deformation Zone, the MAG survey results accentuate the potential for the Property to host other styles of mineralization including:

Magmatic copper, nickel, platinum-group elements mineralization within previously unrecognized bodies of differentiated gabbroic rocks (Dinel and Pettigrew, 2008).
Banded iron formation hosted gold mineralization.
Lode gold mineralization related to D2 structures.
Felsic intrusive related gold mineralization.
Base metal mineralization.

To prepare for the 2020 field season, GoldON has hired Orix Geoscience to do a compilation and reinterpretation of all available historical data on the Property. This will include incorporating the new MAG survey data with all known lithological and mineralogical information and known structural measurements to build a comprehensive structural and geological map that will vector fieldwork towards those areas of highest merit for exploration.

"Our team is excited about the initial interpretations from the MAG survey that underscores the potential for the Slate Falls Property to host other styles of mineralization beyond the known gold and silver showings," said Mike Romanik President of GoldON. "We look forward to receiving the recommendations from Orix that will direct our upcoming fieldwork. The goal is to define next stage drill targets on the Property."

Mike Kilbourne, P. Geo, an independent qualified person as defined in National Instrument 43-101, has reviewed and approved the technical contents of this news release on behalf of the Company.

About GoldON Resources Ltd.

GoldON is an exploration company focused on discovery-stage properties located in the prolific gold mining belts of northwestern Ontario, Canada. Active projects include the West Madsen property in the Red Lake Gold Camp, an option/JV with Great Bear Resources; the Bruce Lake property that adjoins BTU Metals' Dixie Halo property and their TNT Target; and the 100% owned Slate Falls project in the Patricia Mining Division, where numerous Au-Ag mineralized zones have been identified over the 13-km breadth of the property. GoldON has 17,208,432 shares issued, all our properties are in good standing and we are fully funded for our 2020 exploration programs.

Additional information is available on our website at https://goldonresources.com; you can download our latest presentation by clicking here and you can follow us on Twitter at https://twitter.com/GoldONResources.

ON BEHALF OF THE BOARD

Signed "Michael Romanik"

Michael Romanik, President
Direct line: (204) 724-0613
Email: romanikm@mymts.net

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: GoldON Resources Ltd.

ReleaseID: 591687

Jaguar Health Submits Final Major Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Chemotherapy-induced Diarrhea in Dogs

Canalevia would be first and only FDA-approved plant-based medicine for 50,000-plus dogs that suffer from diarrhea during chemotherapy

SAN FRANCISCO, CA / ACCESSWIRE / May 28, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that it has submitted to the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) what the Company expects is the final major regulatory filing to support approval of its oral plant-based drug candidate Canalevia™ (crofelemer delayed-release tablets) to treat chemotherapy-induced diarrhea (CID) in dogs.

According to current estimates, more than 230,000 dogs in the U.S. receive chemotherapy treatment for various cancers each year, and roughly one in four will experience diarrhea as a side effect of treatment. There currently is no FDA-approved anti-secretory prescription product to manage this debilitating diarrhea in dogs.

The filing consists of an updated version of the Target Animal Safety technical section of Jaguar's application for conditional approval of Canalevia for CID under the Minor Use/Minor Species (MU/MS) section of The Minor Use and Minor Species Animal Health Act of 2004.

"With this filing, which includes new administrative details, we are confident that CVM will deem our Target Animal Safety technical section Complete," said Dr. Michael Guy, DVM, Ph.D., Jaguar's vice president of preclinical and nonclinical studies.

As previously announced, the technical section contains data from a 2017 safety study indicating that the NOAEL (no-observed-adverse-effect level) of Canalevia in dogs is approximately six times greater than previously demonstrated, and that Canalevia also is safe for use in puppies as young as 12 weeks of age.

In addition to CID, Jaguar also is seeking conditional approval to market Canalevia for exercise-induced diarrhea (EID) in dogs. "We are leveraging many of the same major technical sections from our CID submission for the proposed EID indication," Dr. Guy said. "We expect that Canalevia could be available under conditional approval to treat both CID and EID in the first half of 2021."

"Jaguar is now one important step closer to having our first approved medicine for use in animals," said Jaguar president and chief executive officer Lisa Conte. "We believe Canalevia will be an important treatment option for the 50,000 dogs that suffer from CID each year. And once CID is under control, dogs may better tolerate their chemotherapy."

Jaguar's wholly owned subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), currently markets Mytesi®, another form of crofelemer, for the treatment of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. Crofelemer comes from the Croton lechleri tree, which is responsibly and sustainably harvested in South America.

Napo is pursuing the development of Mytesi to treat cancer therapy-related diarrhea in humans. Conte said that dogs undergoing chemotherapy are an important predictive model for crofelemer's mechanism of action in humans experiencing diarrhea as a result of their cancer treatment.

As previously announced, the CVM has confirmed the completeness of Jaguar's Reasonable Expectation of Effectiveness technical section for CID under MU/MS, as well as the CMC (Chemistry, Manufacturing and Controls) and Environmental Impact technical sections of the Company's applications for conditional approval of Canalevia for both CID and EID.

About Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com.

About Mytesi®

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that the updated version of the Target Animal Safety technical section of the Company's application for conditional approval of Canalevia for CID will be the final major regulatory filing in the Company's effort to gain approval to market Canalevia for CID in dogs, the expectation that CVM will determine that the updated version of the Target Animal Safety technical section is Compete, the expectation that Canalevia could be available under conditional approval for CID and EID in first half of 2021, and the belief that Canalevia will be an important treatment option for the 50,000 dogs that suffer from CID each year. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Some of the factors that could affect our actual results are included in the periodic reports on Form 10-K and Form 10-Q that we file with the Securities and Exchange Commission. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

CONTACT:

Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

ReleaseID: 591690